INKT

MiNK Therapeutics Inc

Apr 02 • 04:00PM ET

10.69

+0.12 1.14 %

Healthcare • Biotechnology • USA • NASD

Peers: VRTX ONC FATE ADAP IMTX PGEN AFMD CGEN KPTI TVRD

Index	-	P/E	-	EPS (ttm)	-2.96	Insider Own	64.83%	Shs Outstand	4.71M	Perf Week	11.01%
Market Cap	53.09M	Forward P/E	-	EPS next Y	-3.45	Insider Trans	-0.06%	Shs Float	1.75M	Perf Month	-2.02%
Enterprise Value	44.91M	PEG	-	EPS next Q	-0.77	Inst Own	3.07%	Short Float	8.55%	Perf Quarter	-4.13%
Income	-12.49M	P/S	-	EPS this Y	-11.43%	Inst Trans	8.71%	Short Ratio	0.52	Perf Half Y	-27.08%
Sales	0.00M	P/B	-	EPS next Y	-5.67%	ROA	-125.20%	Short Interest	0.15M	Perf YTD	-4.13%
Book/sh	-3.02	P/C	3.97	EPS next 5Y	24.32%	ROE	-	52W High	76.00 -85.93%	Perf Year	19.18%
Cash/sh	2.69	P/FCF	-	EPS past 3/5Y	29.40% 9.83%	ROIC	-	52W Low	6.34 68.61%	Perf 3Y	-43.59%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	12.26% 10.05%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-1.96%	Oper. Margin	-	ATR (14)	1.00	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.06	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	52.82	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.06	EPS Q/Q	11.21%	SMA20	5.73%	Beta	0.35	Target Price	43.75
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	-1.96%	Rel Volume	0.12	Prev Close	10.57
Employees	15	LT Debt/Eq	-	Earnings	Mar 31 BMO	SMA200	-18.37%	Avg Volume	289.15K	Price	10.69
IPO	Oct 15, 2021	Option/Short	No / Yes	EPS/Sales Surpr.	23.53% -	Trades		Volume	35,486	Change	1.14%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-15-25	Upgrade	H.C. Wainwright	Neutral → Buy	$35
Jul-14-25	Downgrade	William Blair	Outperform → Mkt Perform

Apr-03-26 07:30AM	MiNK Therapeutics and Memorial Sloan Kettering to Present Phase II Study of agenT-797 Combination in PD-1 Refractory Gastroesophageal Cancer at AACR 2026 (GlobeNewswire)
Apr-02-26 07:30AM	MiNK Therapeutics to Present New Data at ASGCT 2026 Highlighting Context-Dependent Activity of iNKT Cell Therapy (GlobeNewswire)
Apr-01-26 07:30AM	MiNK Therapeutics Announces Abstract Acceptance for Presentation at the American Thoracic Society (ATS) 2026 International Conference (GlobeNewswire)
Mar-31-26 03:01PM	MiNK Therapeutics Inc (INKT) Q4 2025 Earnings Call Highlights: Strategic Advances and Financial ... (GuruFocus.com)
12:43PM	MiNK Therapeutics, Inc. Q4 2025 Earnings Call Summary (Moby)
07:30AM	Loading…
07:30AM	MiNK Therapeutics Reports Q4 and Full Year 2025 Results; Phase 2 Programs Advance with Impactful Non-Dilutive Momentum (GlobeNewswire)
Mar-17-26 07:30AM	MiNK Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Highlight Platform Expansion Across iNKT Cell Therapy Programs (GlobeNewswire)
Mar-10-26 09:47AM	MiNK Therapeutics Pediatric Cancer Breakthrough Sparks Stock Rally (Benzinga) +29.28%
05:30AM	MiNK Therapeutics Announces Collaboration with C-Further to Advance PRAME-Targeted iNKT Cell Therapy for Pediatric Cancers (GlobeNewswire)
Feb-03-26 09:30PM	MiNK Therapeutics Presents New Data of allo-iNKT Cell Therapy as a Potential Disease-Modifying Approach in Idiopathic Pulmonary Fibrosis at Keystone Symposia (GlobeNewswire)
Jan-08-26 12:00PM	MiNK Therapeutics and University of Wisconsin-Madison Announce Phase 1 Clinical Trial of Allo-iNKT Cell Therapy (AgenT-797) to Evaluate Prevention of Graft-Versus-Host Disease (GlobeNewswire)
Nov-20-25 11:42AM	MiNK Therapeutics Announces New Data Showing MiNK-215 Drives Potent Anti-Tumor Activity in Treatment-resistant Solid Tumors (GlobeNewswire)
Nov-14-25 04:01PM	MiNK Therapeutics Inc (INKT) Q3 2025 Earnings Call Highlights: Promising Clinical Results and ... (GuruFocus.com) -5.88%
07:30AM	MiNK Therapeutics Reports Q3 2025 Results and Accelerates iNKT Platform Toward Pivotal Development Across Oncology, Pulmonary Disease, and Transplantation (GlobeNewswire)
Nov-07-25 09:00AM	MiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1-Refractory Solid Tumors at SITC 2025 (GlobeNewswire)
09:07AM	Loading…
Nov-05-25 09:07AM	MiNK Therapeutics to Report Third Quarter 2025 Financial Results and Highlight Clinical and Corporate Milestones Advancing iNKT Platform Toward Pivotal Development (GlobeNewswire)
Oct-30-25 09:00AM	MiNK Therapeutics to Present Late-Breaking Data on AgenT-797 in Solid Tumors at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting (GlobeNewswire)
Sep-29-25 07:30AM	MiNK Therapeutics Appoints Colonel (Ret.) John B. Holcomb, MD, to Board of Directors (GlobeNewswire)
Sep-25-25 07:30AM	MiNK Therapeutics Dr. Jennifer Buell to Deliver Featured Plenary at 10th Annual CAR-TCR Summit in Boston, MA (GlobeNewswire) -5.09%
Sep-18-25 07:30AM	MiNK Therapeutics Appoints Dr. Terese C. Hammond to Accelerate iNKT Pipeline to Pivotal Development (GlobeNewswire) +7.79%
Aug-22-25 05:40AM	New Strong Sell Stocks for August 22nd (Zacks)
Aug-15-25 09:32AM	Target downgraded, Salesforce upgraded: Wall Street's top analyst calls (The Fly)
Aug-14-25 07:30AM	MiNK Therapeutics Reports Clinical and Strategic Milestones and Second Quarter 2025 Results (GlobeNewswire) -12.46%
Jul-31-25 08:30AM	MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report (GlobeNewswire) -8.34%
07:30AM	Agenus to Provide Corporate Update and Second Quarter 2025 Financial Report (Business Wire)
Jul-15-25 08:21AM	MiNK Therapeutics Announces Frontiers in Immunology Publication Highlighting iNKT Cells as a Dual-Function Platform Key to Overcoming Barriers in Solid Tumor Cell Therapy (GlobeNewswire) -31.03%
Jul-14-25 08:04AM	MiNK Therapeutics stock falls after William Blair downgrade (Investing.com) -36.71%
Jul-11-25 07:30AM	MiNK Therapeutics Announces Publication of Complete Remission Following Allogeneic iNKT Cell Therapy in Metastatic Testicular Cancer (GlobeNewswire) +730.14%
Jun-10-25 01:33PM	MiNK Therapeutics Announces Virtual Annual Shareholders Meeting (GlobeNewswire) +5.84%
Jun-02-25 09:29AM	MiNK Therapeutics Awarded Prestigious NIAID Grant to Advance Allo-iNKT Cell Therapy for Prevention of GvHD in Stem Cell Transplant Patients (GlobeNewswire)
03:09AM	Loading…
May-16-25 03:09AM	MiNK Therapeutics Inc (INKT) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com) +5.01%
May-15-25 11:48PM	Q1 2025 Mink Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
07:30AM	MiNK Therapeutics Reports Q1 2025 Results and Highlights Clinical & Strategic Progress (GlobeNewswire)
May-05-25 12:30PM	MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report (GlobeNewswire)
Mar-19-25 03:01AM	MiNK Therapeutics Inc (INKT) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
Mar-18-25 11:42PM	Q4 2024 Mink Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
07:30AM	MiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business Progress (GlobeNewswire)
Mar-04-25 07:30AM	MiNK Therapeutics to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report (GlobeNewswire) -7.88%
Feb-24-25 08:30AM	MiNK Therapeutics Presents First-in-Kind Allo-iNKTs Combination Data in 2L Gastric Cancer at AACR IO Annual Meeting (GlobeNewswire) +5.45%
Feb-20-25 07:30AM	MiNK Therapeutics Regains Full Compliance with Nasdaq Listing Requirements (GlobeNewswire)
Feb-12-25 01:00PM	MiNK Therapeutics to Present Updated Data from Phase 2 Study Testing AgenT-797 in Gastric Cancer at AACR IO Annual Meeting (GlobeNewswire) -7.86%
Jan-23-25 02:13PM	MiNK Therapeutics Targets Immune Reconstitution to Combat Advanced Gastroesophageal Cancers with Novel Combination of Allo-iNKTs plus BOT/BAL at ASCO GI (GlobeNewswire)
Dec-18-24 09:45AM	MiNK Therapeutics to Present iNKT Cell Therapy in Gastric Cancer at ASCO GI Annual Meeting (GlobeNewswire) -14.02%
Nov-15-24 02:17AM	Q3 2024 Mink Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
02:09AM	MiNK Therapeutics Inc (INKT) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
Nov-14-24 07:00AM	MiNK Therapeutics Reports Third Quarter 2024 Results and Business Update (GlobeNewswire) -5.59%
Nov-11-24 07:30AM	MiNK Therapeutics to Provide Corporate Update and Third Quarter 2024 Financial Report (GlobeNewswire)
Nov-07-24 10:00AM	MiNK's iNKT Cell Therapy Shows Potential for Optimal Multi-Combination for Resistant Solid Cancers at SITC 2024 (GlobeNewswire)
Oct-31-24 09:15AM	MiNK Therapeutics Announces Appointment of Dr. Robert Kadlec to Board of Directors (GlobeNewswire)
Oct-09-24 06:15PM	MiNK Therapeutics Inc (INKT) Q2 2024 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
Oct-08-24 07:30AM	MiNK Therapeutics and Autonomous Therapeutics Announce Collaboration to Develop Novel Therapies Targeting Metastatic Tumors (GlobeNewswire)
Oct-04-24 09:10AM	MiNK Therapeutics to Present Data From iNKT Cell Programs at SITC 2024 (GlobeNewswire)
Sep-03-24 07:30AM	MiNK Therapeutics to Participate in H.C. Wainwright Global Investment Conference (GlobeNewswire)
Aug-13-24 07:00AM	MiNK Reports Second Quarter 2024 Results and Business Update (GlobeNewswire)
Aug-01-24 07:30AM	MiNK Therapeutics to Provide Corporate Update and Second Quarter 2024 Financial Report (GlobeNewswire)
Jul-31-24 07:30AM	MiNK Therapeutics Regains Compliance with Nasdaq Capital Market Requirement (GlobeNewswire)
Jul-11-24 12:00PM	MiNK Therapeutics, Inc. (INKT) Upgraded to Strong Buy: Here's What You Should Know (Zacks) +11.36%
Jun-05-24 07:30AM	MiNK Therapeutics Announces Virtual Annual Shareholders Meeting (GlobeNewswire)
May-22-24 07:30AM	MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting (GlobeNewswire)
May-15-24 03:04AM	MiNK Therapeutics Inc (INKT) Q1 2024 Earnings Call Transcript Highlights: Strategic Reductions ... (GuruFocus.com) -7.14%
May-14-24 11:52AM	INKT Stock Earnings: MiNK Therapeutics Beats EPS for Q1 2024 (InvestorPlace) +14.31%
07:30AM	MiNK Reports First Quarter 2024 Results (GlobeNewswire)
May-13-24 07:30AM	MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer (GlobeNewswire) +8.87%
Apr-30-24 07:30AM	MiNK to Provide Corporate Update and First Quarter 2024 Financial Report (GlobeNewswire)
Apr-08-24 12:00PM	MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR (GlobeNewswire) -15.38%
Mar-25-24 12:00PM	All You Need to Know About MiNK Therapeutics, Inc. (INKT) Rating Upgrade to Buy (Zacks) +5.47%
Mar-22-24 01:25PM	MiNK Therapeutics, Inc. (NASDAQ:INKT) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-21-24 11:06PM	Q4 2023 Mink Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
11:53AM	INKT Stock Earnings: MiNK Therapeutics Misses EPS for Q4 2023 (InvestorPlace)
07:00AM	MiNK Reports Fourth Quarter and Year-End 2023 Results (GlobeNewswire)
Mar-07-24 07:30AM	MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report (GlobeNewswire)
Mar-06-24 08:30AM	MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024 (GlobeNewswire)
Feb-14-24 08:00AM	First Refractory Gastric Cancer Patient Dosed in Phase 2 Trial with Novel Combination of MiNK's Allogeneic INKT Cell Therapy and Agenus' Botensilimab and Balstilimab (GlobeNewswire) +7.75%
Feb-06-24 08:00AM	MiNK Therapeutics' AgenT-797 Shows Promising Results in the Treatment of Severe Acute Respiratory Distress, Published in Nature Communications (GlobeNewswire) +10.25%
Jan-30-24 08:00AM	MiNK's AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene (GlobeNewswire)
Dec-20-23 07:30AM	ImmunoScape and MiNK Therapeutics Collaborate to Accelerate Novel TCR Identification and Therapeutic Development (GlobeNewswire)
Nov-09-23 08:05AM	MiNK Therapeutics Inc (INKT) Reports Q3 2023 Results: Clinical Progress Amid Financial Challenges (GuruFocus.com) -6.72%
07:00AM	MiNK Therapeutics Reports Third Quarter 2023 Results (GlobeNewswire)
Nov-03-23 12:00PM	MiNK Therapeutics Presents Clinical Activity and Long-Term Persistence of Allogeneic iNKT Cells in Solid Tumors at SITC 2023 (GlobeNewswire) +13.59%
Oct-30-23 08:00AM	MiNK to Provide Third Quarter 2023 Financial Report and Corporate Update (GlobeNewswire) +7.62%
Sep-27-23 09:05AM	MiNK Therapeutics To Present Data Update From Allogeneic iNKT Cells in Solid Tumors at SITC 2023 (GlobeNewswire)
Aug-24-23 08:30AM	MiNK Therapeutics to Participate in September Investor Conferences (GlobeNewswire) -8.24%
Aug-10-23 07:30AM	MiNK Therapeutics Reports Second Quarter 2023 Results (GlobeNewswire) +6.67%
Jul-28-23 08:30AM	MiNK to Provide Second Quarter 2023 Financial Report and Corporate Update (GlobeNewswire)
Jun-05-23 07:30AM	MiNK Therapeutics Announces Virtual Annual Shareholders Meeting (GlobeNewswire)
May-22-23 08:30AM	MiNK Presents Clinical Data on Allogeneic iNKT Cells (agenT-797) in Severe Respiratory Distress at the American Thoracic Society International Conference (GlobeNewswire) +16.85%
May-18-23 08:30AM	MiNK's Novel FAP-CAR-iNKT Presented at ASGCT (GlobeNewswire)
May-11-23 08:00AM	MiNK Therapeutics Reports Corporate Update and First Quarter 2023 Financial Results (GlobeNewswire) +7.28%
Apr-27-23 08:30AM	MiNK Therapeutics to Report First Quarter 2023 Corporate Update and Financial Results (GlobeNewswire) -8.29%
Apr-18-23 01:32PM	MiNK Therapeutics Announces Clinical Data of Allogeneic iNKT Cells (agenT-797) in Solid Tumor Cancers at the AACR Annual Meeting (GlobeNewswire)
Apr-16-23 08:03AM	We're Keeping An Eye On MiNK Therapeutics' (NASDAQ:INKT) Cash Burn Rate (Simply Wall St.)
Apr-04-23 09:55AM	MiNK Therapeutics, Inc. (INKT) Could Find a Support Soon, Here's Why You Should Buy the Stock Now (Zacks)
Mar-30-23 08:41AM	Agenus Announces Dividend of 5 Million Shares of MiNK Therapeutics (Business Wire) -6.38%
Mar-29-23 12:00PM	MiNK Therapeutics, Inc. (INKT) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Mar-24-23 07:36AM	MiNK Therapeutics, Inc. (NASDAQ:INKT) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-21-23 08:00AM	MiNK Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Mar-15-23 08:45AM	MiNK Therapeutics to Present Updated Clinical Data of allo-iNKT Cell Therapy in Solid Tumors at AACR Annual Meeting (GlobeNewswire) -5.63%
Mar-07-23 09:00AM	MiNK Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire) +7.35%
Feb-16-23 09:28AM	MiNK Therapeutics to Participate in HC Wainwright Cell Therapy Virtual Conference (GlobeNewswire)
Jan-11-23 02:25PM	MiNK Therapeutics to Participate in B. Riley Securities Oncology Conference (GlobeNewswire)

MiNK Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of allogeneic invariant natural killer T cell therapies to treat cancer and other immune mediated diseases. The company was founded in 2017 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Ryan Barbara	Director	Mar 10 '26	Sale	15.40	1,300	20,017	20,406	Mar 11 06:22 PM
Ryan Barbara	Director	Mar 09 '26	Sale	10.17	200	2,034	21,706	Mar 11 06:22 PM
Ryan Barbara	Director	Feb 27 '26	Sale	10.86	400	4,343	22,006	Mar 04 04:45 PM
Ryan Barbara	Director	Mar 02 '26	Sale	10.83	100	1,083	21,906	Mar 04 04:45 PM
Agenus Inc.	Owner	Aug 29 '25	Proposed Sale	15.98	786,750	12,572,265		Aug 29 05:02 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

INKT

MiNK Therapeutics Inc

Upgrade your Finviz experience